In brief: PBS restrictions for blood cancer therapies; Severe haemophilia A; DOAC dipstick test

Reduced PBS restrictions recommended for blood cancer therapies PBS prescribing restrictions should be eased for some blood cancer therapies, according to the latest recommendations from the Pharmaceutical Benefit Advisory Committee (PBAC). At its November 2020 meeting the PBAC recommended decreasing the PBS restriction level for nilotinib and dasatinib to Authority Required (Telephone) for initial treatment ...

Already a member?

Login to keep reading.

© 2021 the limbic